Edition:
United States

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

34.21USD
15 Dec 2017
Change (% chg)

$0.34 (+1.00%)
Prev Close
$33.87
Open
$33.89
Day's High
$34.58
Day's Low
$33.48
Volume
595,630
Avg. Vol
148,564
52-wk High
$38.86
52-wk Low
$15.97

Chart for

About

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is... (more)

Overall

Beta: --
Market Cap(Mil.): $1,740.04
Shares Outstanding(Mil.): 50.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​

* Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018

Nov 06 2017

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

Oct 16 2017

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Oct 16 Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

Oct 16 2017

BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

* Aimmune Therapeutics announces clinical collaboration to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

Oct 16 2017

BRIEF-Aimmune Therapeutics qtrly net loss per common share, basic and diluted $0.65

* Aimmune Therapeutics announces second quarter 2017 financial results

Aug 08 2017

BRIEF-Aimmune enrolls first patient in Artemis European Phase 3 clinical trial

* Aimmune Therapeutics enrolls first patient in Artemis (ARC010) European Phase 3 clinical trial of AR101 for the treatment of peanut allergy Source text for Eikon: Further company coverage:

Jul 05 2017

Earnings vs. Estimates